NEW YORK, September 8, 2014 /PRNewswire/ --
Today, Analysts Review released its research reports regarding Mead Johnson Nutrition Company (NYSE: MJN), Philip Morris International, Inc. (NYSE: PM), Johnson Controls Inc. (NYSE: JCI), Actavis plc (NYSE: ACT) and Bristol-Myers Squibb Company (NYSE: BMY). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6279-100free.
--
Mead Johnson Nutrition Company Research Reports
On September 3, 2014, shares in Mead Johnson Nutrition Company (Mead Johnson) declined 1.52% to end the trading session at $93.93, compared to its previous day's close of $95.38. Opening at $95.46, the shares of the Company fluctuated in a range of $93.87 to $95.51. The stock was trading above its 50-day moving average of $93.72 and 200 day moving average of $85.97. The stock underperformed Dow Jones Industrial Average Index which returned 0.06% on the same day. The full research reports on Mead Johnson are available to download free of charge at:
http://www.analystsreview.com/Sep-08-2014/MJN/report.pdf
--
Philip Morris International, Inc. Research Reports
Under the Investor Calendar Section of its website, Philip Morris International, Inc. (Philip Morris) posted a tentative date of October 16, 2014 for its Q3 2014 earnings release. According to Zacks Investment research, the consensus EPS forecast for the current quarter is $1.35, which is above the EPS of $1.24 recorded in the last reported quarter. The full research reports on Philip Morris are available to download free of charge at:
http://www.analystsreview.com/Sep-08-2014/PM/report.pdf
--
Johnson Controls Inc. Research Reports
On September 3, 2014, Johnson Controls Inc., (Johnson Controls) reported that it has awarded 14 suppliers at its fifth yearly Supplier Excellence Recognition awards function. The Company in the Category of Excellence in Execution, honored Future Electronics with Gold award; Arkema Inc. with silver award, and five others with the Bronze award. The Company also honored suppliers based on their leadership in various areas. Amongst others, W.W. Grainger, Inc. was honored for its leadership in innovation, Philips Lighting, NA for its leadership in sustainability, WEG Electric Corp. for Continuous Improvement and Allied Machinery Co., Ltd. for its contribution in global growth. The full research reports on Johnson Controls are available to download free of charge at:
http://www.analystsreview.com/Sep-08-2014/JCI/report.pdf
--
Actavis plc Research Reports
On September 2, 2014, Actavis plc (Actavis) announced that U.S. Food and Drug Administration (FDA) has acknowledged its New Drug Application (NDA) filing for eluxadoline, an investigational drug for the treatment of diarrhea and abdominal pain in men and women with diarrhea predominant Irritable Bowel Syndrome (IBS-D). The filing has been granted a priority assessment status by the FDA. According to the Company, the NDA for eluxadoline is built on the outcomes of two Phase III clinical studies which met their primary endpoints. The Company states that the 12- week efficacy portion of the studies highlights substantial superiority over placebo in the composite endpoint of the simultaneous improvement in both pain and diarrhea at both 75mg and 100mg doses. Pursuant to pre-NDA discussions with FDA, Actavis is planning to file an amendment to the NDA with supplementary data from a study that was continuing at the time of submission. As per the Company, this might result in an extension of the Prescription Drug User Fee Act (PDUFA) date by three months, and into Q2 2015. The full research reports on Actavis are available to download free of charge at:
http://www.analystsreview.com/Sep-08-2014/ACT/report.pdf
--
Bristol-Myers Squibb Company Research Reports
On September 2, 2014, Bristol-Myers Squibb Company (Bristol-Myers Squibb) reported that it will participate at the Morgan Stanley 2014 Global Health Care Conference on September 8, 2014 in New York. Giovanni Caforio, Chief Operating Officer, Bristol-Myers Squibb will discuss about the Company at 2:00 p.m. EDT. A live webcast of the Conference will be available at the Company's website. The full research reports on Bristol-Myers are available to download free of charge at:
http://www.analystsreview.com/Sep-08-2014/BMY/report.pdf
--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.
===============
EDITOR'S NOTES:
===============
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] www.analystsreview.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] www.analystsreview.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] www.analystsreview.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts Review
